A groundbreaking blood test developed by Grail claims to identify a wide range of cancers, potentially revolutionizing early detection methods. The test, called Galleri, is now under review by an independent panel of experts who will determine whether it meets the criteria for FDA approval. If approved, it could offer a non-invasive alternative to traditional cancer screening, which often relies on more invasive procedures. The decision hinges on whether the test’s accuracy and reliability justify its use in clinical settings.
The company Grail says its Galleri blood test can detect up to 50 forms of cancer. An independent panel of experts will decide if the test should be recommended for FDA approval.
